Cargando…
High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma
BACKGROUND: Adaptive resistance and side effects of sorafenib treatment result in unsatisfied survival of patients with hepatocellular carcinoma (HCC). Palmitoyl-protein thioesterase 1 (PPT1) plays a critical role in progression of various cancers. However, its role on prognosis and immune infiltrat...
Autores principales: | Xu, Jianjun, Su, Zhe, Cheng, Xiang, Hu, Shaobo, Wang, Wenjie, Zou, Tianhao, Zhou, Xing, Song, Zifang, Xia, Yun, Gao, Yang, Zheng, Qichang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917761/ https://www.ncbi.nlm.nih.gov/pubmed/35277179 http://dx.doi.org/10.1186/s12935-022-02508-y |
Ejemplares similares
-
PPT-DB: the protein property prediction and testing database
por: Wishart, David S., et al.
Publicado: (2008) -
An over-expression system for characterizing Ppt1 function in Drosophila
por: Korey, Christopher A, et al.
Publicado: (2003) -
Quantitative analysis of PPT1 interactome in human neuroblastoma cells
por: Scifo, Enzo, et al.
Publicado: (2015) -
Identification of PPT1 as a lysosomal core gene with prognostic value in hepatocellular carcinoma
por: Tian, Wei, et al.
Publicado: (2023) -
Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma
por: Weng, Jialei, et al.
Publicado: (2023)